Market Overview

UPDATE: Bank of America Raises PO to $7 on Arena Pharmaceuticals on Lorcaserin Aproval

Share:
Related ARNA
Arena Pharmaceuticals Hires Kevin Lind As CFO
Arena Gets USAN Approval Of Nonproprietary Name 'Etrasimod' For Its Drug Candidate APD334

Bank of America reiterates its Underperform rating on Arena Pharmaceuticals (NASDAQ: ARNA) but raises its price target from $5 to $7.

Bank of America comments, "Following FDA approval of ARNA's obesity drug lorcaserin (trade name Belviq), we raised our NPV to $7/sh (from $5). Our caution on the stock has been due to a combination of delay expectations and a modest market opportunity. This latter concern is unchanged based on the drug's marginal efficacy (3-4% PBO-adjusted weight loss) and various safety concerns. With an EV of $2.3bn versus $2.5bn for VVUS, we view ARNA's current valuation as rich and remain Underperform."

ARNA closed at $11.39 on Wednesday.

Latest Ratings for ARNA

DateFirmActionFromTo
Nov 2013WallachbethInitiates Coverage onBuy
Oct 2013Cowen & CompanyInitiates Coverage onMarket Perform
Oct 2013Piper JaffrayMaintainsOverweight

View More Analyst Ratings for ARNA
View the Latest Analyst Ratings

Posted-In: Bank of AmericaAnalyst Color Price Target Reiteration Intraday Update Analyst Ratings

 

Related Articles (ARNA)

View Comments and Join the Discussion!